JP2016537384A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537384A5
JP2016537384A5 JP2016533073A JP2016533073A JP2016537384A5 JP 2016537384 A5 JP2016537384 A5 JP 2016537384A5 JP 2016533073 A JP2016533073 A JP 2016533073A JP 2016533073 A JP2016533073 A JP 2016533073A JP 2016537384 A5 JP2016537384 A5 JP 2016537384A5
Authority
JP
Japan
Prior art keywords
methyl
dimethyl
chlorophenyl
oxo
dihydropyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/066199 external-priority patent/WO2015075665A1/en
Publication of JP2016537384A publication Critical patent/JP2016537384A/ja
Publication of JP2016537384A5 publication Critical patent/JP2016537384A5/ja
Pending legal-status Critical Current

Links

JP2016533073A 2013-11-21 2014-11-20 ピロロピロロン誘導体およびbet阻害剤としてのその使用 Pending JP2016537384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13193825.0 2013-11-21
EP13193825 2013-11-21
PCT/IB2014/066199 WO2015075665A1 (en) 2013-11-21 2014-11-20 Pyrrolopyrrolone derivatives and their use as bet inhibitors

Publications (2)

Publication Number Publication Date
JP2016537384A JP2016537384A (ja) 2016-12-01
JP2016537384A5 true JP2016537384A5 (enExample) 2017-12-21

Family

ID=49596200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533073A Pending JP2016537384A (ja) 2013-11-21 2014-11-20 ピロロピロロン誘導体およびbet阻害剤としてのその使用

Country Status (10)

Country Link
US (1) US9550796B2 (enExample)
EP (1) EP3071571A1 (enExample)
JP (1) JP2016537384A (enExample)
KR (1) KR20160086930A (enExample)
CN (1) CN105916857B (enExample)
AU (1) AU2014351413B2 (enExample)
CA (1) CA2931249A1 (enExample)
EA (1) EA029269B1 (enExample)
MX (1) MX2016006667A (enExample)
WO (1) WO2015075665A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539960A4 (en) 2016-11-10 2020-03-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. NITROGEN MACROCYCLIC COMPOUND, ITS PREPARATION METHOD, ITS PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
JP2021008407A (ja) * 2017-10-02 2021-01-28 武田薬品工業株式会社 複素環化合物
BR112021017042A2 (pt) * 2019-03-15 2021-11-16 Nippon Soda Co Composto, e, fungicida para agricultura ou horticultura
US20220378923A1 (en) 2019-09-30 2022-12-01 Kyowa Kirin Co., Ltd. Bet degrader
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
JPS4822715B1 (enExample) 1970-12-28 1973-07-07
JPS5427356B2 (enExample) 1972-03-31 1979-09-10
US4258187A (en) 1977-06-16 1981-03-24 E. I. Du Pont De Nemours And Company Process for preparing quinazolinone oxides
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5721388A (en) 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
DE3420799A1 (de) 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DE69738754D1 (de) 1996-07-05 2008-07-17 Cancer Rec Tech Ltd Hemmer der interaktion zwischen p53 und mdm2
HRP980143A2 (en) 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ(adp−リボース)ポリメラーゼ阻害剤
US6479499B1 (en) 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
BR0113176A (pt) 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
AU2003235504A1 (en) 2002-05-13 2003-11-11 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
CA2536313A1 (en) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
PT1663185E (pt) 2003-09-22 2009-02-16 Onepharm Res & Dev Gmbh Prevenção e tratamento de perda óssea induzida por inflamação e/ou imunomediada
KR20060127413A (ko) 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 cis-이미다졸린
BRPI0511748A (pt) 2004-06-01 2008-01-02 Univ Virginia composição farmacêutica, métodos para tratar cáncer e uma doença ou distúrbio associado com angiogênese em um indivìduo em necessidade, para inibir a proliferação de células endoteliais vasculares e cancerosas, e para preparar sc-2-71 e análogos do mesmo, rótulo de fotoafinidade de sc-2-71, método para interromper a polimerização dos microtúbulos em uma célula, e para identificar um análogo, análogo, e, kit para administrar uma composiçaõ farmacêutica a um indivìduo
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160869A1 (en) 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1868685A2 (en) 2005-03-18 2007-12-26 onepharm GmbH 11ß-HYDROXYSTEROID DEHYDROGENASES
WO2006100038A1 (en) 2005-03-23 2006-09-28 Syngenta Participations Ag Triazolopyrimidine derivatives useful as fungicides
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
EP1963326A1 (en) 2005-12-12 2008-09-03 NERVIANO MEDICAL SCIENCES S.r.l. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
WO2007096334A1 (en) * 2006-02-24 2007-08-30 Pfizer Italia Srl Pyrrolopyrrolones active as kinase inhibitors
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
AU2007260040A1 (en) 2006-06-14 2007-12-21 4Sc Ag Pyrazolopyrimidones
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
WO2008034039A2 (en) 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
TW200843739A (en) 2007-03-30 2008-11-16 Shionogi & Co Novel pyrrolinone derivative and composition containing the same
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
JP5637562B2 (ja) 2008-09-25 2014-12-10 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
JP2012505231A (ja) 2008-10-08 2012-03-01 ブリストル−マイヤーズ スクイブ カンパニー アゾロピロロンメラニン凝集ホルモン受容体−1アンタゴニスト
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
US20120208204A1 (en) 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
CA2817585A1 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) * 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
CN104080787B (zh) 2011-11-29 2016-09-14 诺华股份有限公司 吡唑并吡咯烷化合物
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN104334526A (zh) 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
WO2014191894A1 (en) * 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease

Similar Documents

Publication Publication Date Title
JP2016537384A5 (enExample)
JP2022184886A5 (enExample)
RU2424242C2 (ru) Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
JP2018529731A5 (enExample)
JP2016520116A5 (enExample)
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP2020504136A5 (enExample)
JP2019535664A5 (enExample)
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8
JP2016520118A5 (enExample)
JP2012515786A5 (enExample)
RU2018123779A (ru) Новые соединения
JP2016529292A5 (enExample)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2015517566A5 (enExample)
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP2015508075A5 (enExample)
JP2003531210A5 (enExample)
RU2017121278A (ru) Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use
JP2012532931A5 (enExample)
JP2011500774A5 (enExample)